Related Experiment Videos
Catabolic effect in premature infants with early dexamethasone treatment
1Department of Pediatrics, China Medical College Hospital, Taichung, Taiwan.
Acta Paediatrica (Oslo, Norway : 1992)
|December 1, 1996
Summary
Dexamethasone therapy in premature infants significantly increased amino acid levels and urinary 3-methylhistidine (3MH), indicating heightened protein catabolism. These findings suggest potential risks associated with early dexamethasone use.
Area of Science:
- Neonatal Medicine
- Biochemistry
- Pharmacology
Background:
- Bronchopulmonary dysplasia (BPD) is a common complication in premature infants.
- Dexamethasone is used to prevent BPD, but its effects on protein metabolism are not fully understood.
Purpose of the Study:
- To evaluate the catabolic effects of early dexamethasone therapy on protein metabolism in premature infants.
- To assess changes in amino acid concentrations and urinary 3-methylhistidine (3MH) levels.
Main Methods:
- A double-blind, controlled study involving 28 premature infants.
- Infants received either dexamethasone (0.5 mg/kg/day i.v.) or a saline control.
- Amino acid analysis of blood samples and urinary 3MH measurements were performed.
Main Results:
- Dexamethasone-treated infants showed a significant increase in amino acid concentrations, including alanine, glutamine, citrulline, ornithine, and cystine.
- The 3-methylhistidine (3MH) to creatinine ratio in urine increased in the dexamethasone group.
- These changes suggest an increase in protein catabolism.
Conclusions:
- Early dexamethasone therapy in premature infants appears to increase protein catabolism.
- Metabolic monitoring is crucial for infants receiving dexamethasone treatment.